We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
30 result(s) found, displaying 1 to 10
-
Prescription medicine decision summaryPluvicto (Lutetium (177Lu) vipivotide tetraxetan) has been approved for the treatment of adult patients with prostate cancer who have received prior treatments.
-
Australian Public Assessment Report (AusPAR)AusPAR for Cosentyx (secukinumab) for the treatment of plaque psoriasis, psoriatic arthritis and axial spondyloarthritis etc.
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Inclisiran
-
-
Prescription medicine decision summaryTGA decision: Zolgensma (onasemnogene abeparvovec) is approved to treat patients less than 9 months old with symptomatic/pre-symptomatic SMA.
-
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Pasireotide (as diaspartate)
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Deferasirox
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Imatinib
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Nabiximols